Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.
Lianna J MarksQinglin PeiRizvan BushAllen BuxtonBurton AppelKara M KellyCindy L SchwartzDebra L FriedmanPublished in: Pediatric blood & cancer (2018)
Children and adolescents with intermediate-risk LPHL represent ideal candidates for response-adapted therapy based on their favorable outcomes. The majority of patients treated with the ABVE-PC backbone achieve RER with CR status and can be treated successfully without IFRT.